All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 650+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Johnson & Johnson’s medtech division DePuy Synthes lands FDA clearance for spinal surgery robot
Medtech, spinal surgery, robotic surgery - Read more

Supernus Pharmaceuticals resubmits FDA NDA for apomorphine infusion device
Small molecule, medical device, infusion device, Parkinson’s disease - Read more

THE GOOD
Business Development

Vir Biotechnology’s worldwide license agreement with Sanofi for three clinical stage T-cell engager assets
T-cell engager, solid tumor, cancer - Read more

THE GOOD
Company Launches

Jade Biosciences launches with $80M, fourth Paragon Therapeutics venture
Inflammatory disease, immunological disease, autoimmune - Read more

THE GOOD
Earnings & Finances

Biogen, Eisai’s Leqembi climb higher in Japan
Monoclonal antibody, Alzheimer’s disease - Read more [Paywall]

Vertex Pharmaceuticals boosts 2024 revenue outlook on increasing Casgevy sales
Gene therapy, beta thalassemia - Read more

THE GOOD
Fundraises

Amlogenyx (Ultragenyx Pharmaceutical subsidiary) $14M Seed raise
Gene therapy, Alzheimer’s disease - Read more

Mindera Health $14M convertible note financing
Skin analytics, dermatology, biomarker, medical device - Read more

Protembis €20M ($22M) venture financing
Medical device, heart surgery, cerebral embolic protection - Read more

THE GOOD
Mergers & Acquisitions

WinHealth Pharma acquires Chinese operations of Kyowa Kirin for CNY 750M ($105M)
Monoclonal antibody, hypophosphataemia, tumour-induced osteomalacia, lymphoma, cancer - Read more

THE GOOD
Partnerships

BridGene Biosciences expands strategic collab with Galapagos, total deal up to $159M
Small molecule, drug development - Read more

THE GOOD
Patient Access

Eli Lilly’s Zepbound, Mounjaro no longer on US drug shortage list
GLP-1, obesity, diabetes, weight loss - Read more

THE GOOD
Research

Potential flesh-eating bacteria antibiotic reduces infection and speeds up healing in mine
Small molecule, necrotizing fasciitis - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Clinical Trials

Vertex Pharmaceuticals axes two rare genetic disease meds after disappointing Ph1 biomarker analyses
Small molecule, alpha-1 antitrypsin deficiency (AATD) - Read more

THE BAD
Company Shutdown

Ribon Therapeutics shuts doors
Small molecule, cancer, inflammation, autoimmune - Read more [Paywall]

THE BAD
Earnings & Finances

23andMe board rejects CEO’s take-private offer
Genetic testing - Read more [Paywall]

THE BAD
Politics & Policy

Mass­a­chu­setts state’s $1 bil­lion life sci­ences investment package fails to make it through most recent legislative session
Life science investment, incentives - Read more [Paywall]

THE UGLY
Clinical Trials

Galapagos halts Ph1/2 CAR-T trial over a case of Parkinsonism
CAR-T cell therapy, myeloma, cancer, Parkinson’s-like movement disorder - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.